The Reshoring Paradox: A Paracetamol Case Study
Manufacturing location is a well-established management decision. Reshoring API production adds a condition: proximity and cost are not sufficient; the location also has to be operationally viable once resource use is accounted for. That’s an empirical question, and Life Cycle Assessment is a method well-suited to answering this and an instrument for testing whether reshoring stands up under scrutiny.
Strategic Context
Pharmaceutical resilience is a board-level topic. COVID-19, geopolitical instability, and recurring shortages have exposed the risks of relying on distant Active Pharmaceutical Ingredient manufacturing hubs. For essential medicines like Paracetamol, it is a hard conversation about supply security and industrial sovereignty across Europe.
Moving production to Europe does not automatically make it sustainable. If companies simply replicate linear production systems in Europe, they reduce supply-chain risk while still carrying high resource use, waste, and emissions. The real challenge isn’t just where medicines are made, but how.
This is where circular economy principles matter. Localized production can be redesigned around resource recovery, lower-impact utilities, reusable packaging, and real-time environmental data. Life Cycle Assessment is key to identifying where impact reduction actually pays off.
The Paracetamol API case makes this concrete: the biggest sustainability gains often lie not in the reaction chemistry itself, but in supporting systems such as water, steam, filtration, drying, packaging, and recovery loops. For reshoring to deliver lasting value, production must be local, circular and transparent.
Download the Full PDF Report
Internal Challenge
The understanding of the true environmental impact of Paracetamol API manufacturing at process level was lacking. Generic industry averages weren’t detailed enough to identify where interventions would matter most: which steps actually drove the footprint, whether filtration and drying were as significant as suspected, how much packaging really contributed to carbon and waste, whether the acetic acid by-product was worth recovering, and whether localised production could be genuinely more sustainable rather than just relocated burden.
The working assumption was that chemical synthesis would dominate. It didn’t. The surrounding manufacturing system proved to be the real hotspot: filtration alone accounted for roughly half of the gross footprint, packaging around a quarter, and drying a sixth. Acetylation and crystallization, the reaction steps everyone expected to matter most, made up only a small share. Credible decisions on reshoring, circularity, and investment priorities needed process-level evidence, not broad assumptions.
Strategic Ambition
Beyond Relocation
The ambition is to redefine what sustainable and localised manufacturing can actually look like. Moving production to Europe alone addresses supply security, but not how that production actually performs once running. Reshoring becomes the occasion for a broader redesign, built around circularity and resource efficiency from the beginning.
Closer to Demand
API production moves closer to where it’s actually needed, cutting reliance on the fragile global supply chains that made reshoring urgent in the first place. It’s not just about shorter shipping routes; it’s about having real control over a process that used to sit thousands of miles and several middlemen away.
Circular by Design
By-products get recovered and reused instead of tossed as waste, turning the factory from a straight line into something closer to a loop. What used to be a disposal cost becomes a material stream worth holding onto.
Data as the Decision Tool
Decisions come from close to the actual plant, not industry averages or best guesses. That means knowing exactly which utilities, process steps, and materials are driving impact, instead of pointing investment somewhere broad estimates happen to suggest. This reframed LCA from a reporting exercise into a decision-support tool by showing where the system could be redesigned to cut emissions, recover value, and build a more resilient industry.
The Arcondis Approach
Study Design
Arcondis conducted a localised, gate-to-gate Life Cycle Assessment of 1,000 kg of Paracetamol API production in a German industrial context, following ISO 14040:2026 approach and using close to plant-specific inventory data. The analysis tracked material and energy flows from raw inputs (p-aminophenol and acetic anhydride) through to final API and recovery stages, assessing the system at process-step level.
Defining the System Boundary
A gate-to-gate boundary isolated the manufacturing process itself from upstream raw material production and downstream distribution, letting the team focus on where operational interventions could directly improve performance.
Building a Plant-Specific Inventory
Arcondis first mapped the inputs entering the facility, the utilities powering it through electricity, thermal energy, purified water, WFI systems. The process covered the stages from acetylation through packaging and recovery. Eventually, we also mapped the outputs: API, acetic acid by-product, and solid waste. Plant-specific data showed where burdens actually occurred in the real operating context, rather than where generic datasets might predict.
Quantifying Process-Step Contributions
Filtration turned out to be the single largest contributor to Global Warming Potential, followed by packaging, then drying. Acetylation and crystallization together barely registered by comparison. This shifted the entire improvement logic: the priority became optimizing the surrounding factory systems, not just chasing sustainable synthesis.
Assessing Circular Recovery Potential
Every batch generated close to 400 kilograms of acetic acid as a by-product. Arcondis modeled its recovery through Double Effect Distillation and found that nearly all of it (over 97%) could be captured. The avoided burden of not producing virgin acetic acid far outweighed the extra electricity the recovery process required, delivering a substantial net carbon benefit per batch. Recovered acetic acid could displace virgin material in solvents, coatings, adhesives, textile processing, or wastewater treatment, depending on purity.
Evaluating Waste and Packaging Streams Total solid waste came to roughly 109 kilograms per batch, with more than 90% of it traceable to packaging — mixed materials, plastics, fibre, and cardboard.
Packaging and Waste Reduction
Packaging turned out to be one of the biggest levers in the assessment, driving a quarter of the gross carbon footprint and most of the solid waste. It’s also where EU policy is tightening fastest. The Packaging and Packaging Waste Regulation, directly applicable since 12 August 2026, brings binding rules on minimization, recyclability, reuse, and recycled content, alongside the EU’s existing restrictions on single-use plastics. What used to be operational preference is becoming compliance obligation.
That makes practical routes forward worth prioritizing: returnable pallets and crates instead of single-use cardboard and plastic, supplier take-back for drums and IBCs, reconditioned containers where quality allows, mono-material packaging that’s easier to recycle, recycled-content specifications, and better segregation at the source.
Longer term, the opportunity is to make LCA a living tool for spotting hotspots and building the case for circular investment, rather than a one-off report, ahead of a regulatory timeline that will only get stricter.
How Arcondis Made a Difference
Arcondis shifted the discussion from broad sustainability ambition to operational evidence, connecting Life Cycle Assessment directly to strategic reshoring decisions. The distinctive value came from four things: identifying the true hotspots in filtration, packaging, and drying rather than assuming synthesis was the culprit; quantifying exactly how much acetic acid recovery could transform the carbon balance; translating those findings into a concrete roadmap of utility, recovery, and packaging initiatives; and tying all of it back to Europe’s broader reshoring and resilience agenda.
The conclusion is simple: reshoring is necessary, but not sufficient. Europe’s pharmaceutical future has to be local, circular, and data-driven and the biggest opportunities usually hide in the details: a filtration step, a drying unit, a packaging choice, a recovery loop.
